AIM: Antipsychotic efficacy biomarkers have the potential to improve outcomes in psychotic patients. This study examined the effect of SULT4A1-1 haplotype status (rs2285162 [A]-rs2285167 [G]) on olanzapine response. PATIENTS & METHODS: We evaluated 87 olanzapine treated subjects from Phases 1, 1B and 2 of the CATIE trial for the impact of SULT4A1-1 status on change in Positive and Negative Syndrome Scale (PANSS) total score using two models of response. We also examined weight change. RESULTS: SULT4A1-1-positive status correlated with superior olanzapine response in Phase 1 (p = 0.004 for model 1 and p = 0.001 for model 2) and Phases 1B/2 (p = 0.05 for model 1 and p = 0.007 for model 2). SULT4A1-1-positive subjects gained significantly less weight per month on olanzapine, 0.15 lbs, than did SULT4A1-1-negative subjects, 2.27 lbs (p = 0.04). CONCLUSION: This study provides a second replication of superior olanzapine response in SULT4A1-1-positive subjects compared with SULT4A1-1-negative subjects. SULT4A1-1-positive subjects treated with olanzapine also gained less weight than SULT4A1-1-negative subjects.
AIM: Antipsychotic efficacy biomarkers have the potential to improve outcomes in psychoticpatients. This study examined the effect of SULT4A1-1 haplotype status (rs2285162 [A]-rs2285167 [G]) on olanzapine response. PATIENTS & METHODS: We evaluated 87 olanzapine treated subjects from Phases 1, 1B and 2 of the CATIE trial for the impact of SULT4A1-1 status on change in Positive and Negative Syndrome Scale (PANSS) total score using two models of response. We also examined weight change. RESULTS:SULT4A1-1-positive status correlated with superior olanzapine response in Phase 1 (p = 0.004 for model 1 and p = 0.001 for model 2) and Phases 1B/2 (p = 0.05 for model 1 and p = 0.007 for model 2). SULT4A1-1-positive subjects gained significantly less weight per month on olanzapine, 0.15 lbs, than did SULT4A1-1-negative subjects, 2.27 lbs (p = 0.04). CONCLUSION: This study provides a second replication of superior olanzapine response in SULT4A1-1-positive subjects compared with SULT4A1-1-negative subjects. SULT4A1-1-positive subjects treated with olanzapine also gained less weight than SULT4A1-1-negative subjects.
Entities:
Keywords:
CATIE trial; antipsychotic response; biomarker; weight gain
Authors: Timothy L Ramsey; Herbert Y Meltzer; Guy N Brock; Bharat Mehrotra; Karu Jayathilake; William V Bobo; Mark D Brennan Journal: Pharmacogenomics Date: 2011-04 Impact factor: 2.533
Authors: P F Sullivan; D Lin; J-Y Tzeng; E van den Oord; D Perkins; T S Stroup; M Wagner; S Lee; F A Wright; F Zou; W Liu; A M Downing; J Lieberman; S L Close Journal: Mol Psychiatry Date: 2008-03-18 Impact factor: 15.992
Authors: Vicki L Ellingrod; Brian C Lund; Del Miller; Frank Fleming; Paul Perry; Timothy L Holman; Kristy Bever-Stille Journal: Psychopharmacol Bull Date: 2003
Authors: David H Adams; Sandra Close; Mark Farmen; Anncatherine M Downing; Alan Breier; John P Houston Journal: Hum Psychopharmacol Date: 2008-06 Impact factor: 1.672
Authors: Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; David Salkever; Eric P Slade; Xiaomei Peng; Robert R Conley Journal: BMC Psychiatry Date: 2010-01-07 Impact factor: 3.630